Filing step-change
SYMBIOX · 2026-10
Quarterly observations that moved versus the prior period in 2026-10. Facts only — not a call to act.
Narrative date 2026-10-20 · Evidence medium
Symbiox Sees Stronger Profitability Amidst Declining Revenue Growth Symbiox (SYMBIOX) reported a significant improvement in its gross margin, accelerating to 45.26% in the latest quarter, up from 40.93%.
Raw Evidence
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 45.26 % | 40.93 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 40.93 % | 11.62 | ▲ |
| REVENUE_GROWTH_YOY | -44.3 % | 17.6 | ▼ |
Cite this
Source: Samhati filing step-change for SYMBIOX (2026-10). Observation: Symbiox Sees Stronger Profitability Amidst Declining Revenue Growth Symbiox (SYMBIOX) reported a significant improvement in its gross margin, accelerating to 45.26% in the latest quarter, up from 40.93%. Evidence quality: medium. Not investment advice — no buy, sell, or hold recommendation. Full narrative (Pro): https://samhati.ai/pricing Page: https://samhati.ai/stock/symbiox/q/2026-10
Other periods